- Conditions
- Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Benign Teratoma, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Familial Testicular Germ Cell Tumor, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Male Breast Cancer, Ovarian Immature Teratoma, Ovarian Mature Teratoma, Ovarian Monodermal and Highly Specialized Teratoma, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Extragonadal Seminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Melanoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Rectal Cancer, Stage III Extragonadal Non-seminomatous Germ Cell Tumor, Stage III Extragonadal Seminoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Extragonadal Non-seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Melanoma, Stage IV Ovarian Germ Cell Tumor, Stage IV Rectal Cancer, Testicular Immature Teratoma, Testicular Mature Teratoma
- Interventions
- PD-0332991
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1153–1176
of 54,948
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Leukemia, Myelodysplastic Syndromes
- Interventions
- irofulven
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Barrett's Esophagus With Dysplasia
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Nipent, Cytoxan, Rituxan
- Drug
- Lead sponsor
- East Valley Hematology and Oncology Medical Group
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 52
- States / cities
- Muscle Shoals, Alabama • Burbank, California • Concord, California + 44 more
- Conditions
- Intermittent Claudication, Peripheral Artery Disease
- Interventions
- Placebo, 375 mg CK-2017357, 500 mg CK-2017357
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Santa Ana, California • Stanford, California + 11 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo identical to BI10773 high dose, BI 10773, BI 10773 open label, Placebo identical to BI10773 low dose, Placebo identical to Sitagliptin 100mg, BI10773, Sitagliptin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 986 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 27
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 23 more
- Conditions
- Idiopathic Multicentric Castleman's Disease
- Interventions
- Siltuximab
- Drug
- Lead sponsor
- RECORDATI GROUP
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Lansing, Michigan
- Conditions
- Hemorrhagic Stroke, Ischemic Stroke
- Interventions
- SENSE Device
- Device
- Lead sponsor
- Sense Diagnostics, LLC
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio
- Conditions
- Sarcoma
- Interventions
- cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate, zoledronic acid, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, filgrastim, Mesna
- Drug · Procedure · Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 40 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 70 more
- Conditions
- Stage I Prostate Cancer, Stage II Prostate Carcinoma
- Interventions
- Visualase Thermal Therapy, magnetic resonance imaging
- Device · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 45 Years and older · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hypoglycemia
- Interventions
- Entry of demographic and medical history data into a deidentified database, Blood sample for DNA analysis, Stool sample for microbiome analysis, Mixed meal tolerance test, Continuous glucose monitoring, activity monitor
- Other · Genetic · Diagnostic Test
- Lead sponsor
- Joslin Diabetes Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypoglycemia
- Interventions
- Glucagon
- Drug
- Lead sponsor
- Xeris Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Walnut Creek, California
- Conditions
- Advanced Solid Tumors (Excluding Breast Cancer)
- Interventions
- TAS-102, Placebo
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Peripheral Vascular Diseases, Arterial Occlusive Diseases, Ischemia, Graft Occlusion, Vascular, Hyperplasia
- Interventions
- CGT003 (E2F Duplex Decoy)
- Drug
- Lead sponsor
- Anesiva, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 116
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more
- Conditions
- COVID-19, SARS-CoV 2
- Interventions
- COVID-19 Convalescent Plasma
- Biological
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 2 more
- Conditions
- Schizophrenia, Bipolar Disorder
- Interventions
- Aripiprazole
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Costa Mesa, California + 47 more
- Conditions
- Bladder Cancer
- Interventions
- Not listed
- Lead sponsor
- David Latini
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Metastatic Cancers
- Interventions
- Pembrolizumab, Radiotherapy
- Drug · Radiation
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hodgkins Lymphoma, Non-Hodgkin Lymphoma
- Interventions
- LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES, LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
- Genetic
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Cryptogenic Cirrhosis, Cryptogenic Chronic Hepatitis
- Interventions
- skin punch biopsy collection, Blood collection, Urine sample collection
- Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Opioid-induced Constipation
- Interventions
- Naldemedine, Lubiprostone, Naloxegol
- Drug
- Lead sponsor
- BioDelivery Sciences International
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34,532 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 1
- States / cities
- Wilmington, Delaware
- Conditions
- Breast Cancer
- Interventions
- Gemcitabine, Trastuzumab, Cisplatin
- Drug
- Lead sponsor
- Kari Kendra
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage 0 Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
- Interventions
- Hypofractionated Radiation Therapy
- Radiation
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Lung Transplant
- Interventions
- Procedure
- Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Durham, North Carolina • Cleveland, Ohio